Lung Cancer

The information below is intended for use by health care providers only. Please consult with your health care provider for more information about clinical trials.

A211401 Reducing surgical complications in newly diagnosed lung Ca. patients who smoke cigarettes

Study Details

  • Study Site/Tumor Location: Lung
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

A221504 Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)

Study Details

  • Study Site/Tumor Location: Lung
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

Circulating tumor DNA exposure in peripheral blood using a novel process: A feasibility study

The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the detection of circulating tumor DNA (ctDNA).

Study Details

  • Study Site/Tumor Location: Colon or rectal, pancreatic, gastric, or hepatocellular carcinoma hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma
  • Study Location: Miami Valley Hospital
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Jim Ouellette

Study Contact Information

EA5163 INSIGNA: Firstline Immunotherapy +/- Chemo in Induction/Maintenance or Postprogression in Advanced NSCLC) with Immunobiomarker SIGNature-driven Analysis

Study Details

  • Study Site/Tumor Location: Lung
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

LUNGMAP Screening Biomarker-Driven Therapies and Immunotherapies in Previously- Treated NSCLC

Study Details

  • Study Site/Tumor Location: Lung
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

S1900A LUNGMAP Substudy - Rucaparib in Genomic LOH High And/Or Deleterious BRCA1/2 Mutation Stage IV or Recurrent NSCLC

Study Details

  • Study Site/Tumor Location: Lung
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information